The press service of the Russian Federal Biomedical Agency announced that clinical trials based on mefloquine, hydroxychloroquine and caledavir drugs for the treatment of patients with coronavirus began in Russia, and the press service said, “Clinical trials of hydroxychloroquine and mefloquine and the Russian drug Calidavir have been started, which will be used according to indications A new medical treatment for patients with SARS-CoV-2 emerging infection.”
The press service added, that clinical studies will be conducted in the medical center “Burnazian“, based on the written consent of patients with the new Coronavirus.
Earlier, the press service of the Russian Biomedical Agency had announced that it had provided a treatment regimen for the Coronavirus on the basis of anti-malarial mefloquine.
The agency suggested, to the Russian Ministry of Health, that the treatment system be included in the plan to combat the Coronavirus.
The headquarters of the new Coronavirus control operations announced 1154 new cases of the virus had been recorded in 43 regions of the country, including 697 cases in the capital, Moscow, and 69 in St. Petersburg, bringing the total number of infections to 7,497 cases.
“During the past 24 hours, 1154 new infections with the newly created Coronavirus (COVID-19) were recorded in 43 Russian regions,” bringing the number of confirmed cases in 81 provinces to 7,497.
The headquarters continued in his statement, “88 people have left the hospital during the past 24 hours, after recovering from the virus, bringing the total of those who recovered from the virus to 494 people.“